Rhythm Pharmaceuticals Announces New ICD-10 Diagnosis Code Established for Bardet-Biedl SyndromeGlobeNewsWire • 09/06/23
Rhythm Pharmaceuticals Reports Second Quarter 2023 Financial Results and Business UpdateGlobeNewsWire • 08/01/23
Rhythm Pharmaceuticals Announces Two Publications Detailing Burden of Hyperphagia and Obesity on Patients and Caregivers Living with Bardet-Biedl SyndromeGlobeNewsWire • 07/19/23
Rhythm Pharmaceuticals to Report Second Quarter 2023 Financial Results on Tuesday, August 1, 2023GlobeNewsWire • 07/17/23
Rhythm Pharmaceuticals Presents Data Demonstrating BMI Reduction in Patients with Hypothalamic Obesity Treated with Setmelanotide over Six Months at ENDO 2023GlobeNewsWire • 06/17/23
Rhythm Pharmaceuticals to Present at Goldman Sachs 44th Annual Global Healthcare ConferenceGlobeNewsWire • 06/07/23
Rhythm Pharmaceuticals Announces Health Canada Approval of IMCIVREE® Setmelanotide Injection for Weight Management in Bardet-Biedl Syndrome or Genetically-confirmed Biallelic POMC, PCSK1, or LEPR DeficiencyGlobeNewsWire • 05/08/23
Rhythm Pharmaceuticals Reports First Quarter 2023 Financial Results and Business UpdateGlobeNewsWire • 05/02/23
Will Rhythm Pharmaceuticals, Inc. (RYTM) Report Negative Earnings Next Week? What You Should KnowZacks Investment Research • 04/25/23
Rhythm Pharmaceuticals Announces Commercial Launch of IMCIVREE® (setmelanotide) in Germany for the Treatment of Obesity and Control of Hunger in Bardet-Biedl SyndromeGlobeNewsWire • 04/24/23
Rhythm Pharmaceuticals to Present at 22nd Annual Needham Virtual Healthcare ConferenceGlobeNewsWire • 04/10/23
Rhythm Pharmaceuticals Announces Publication of Bardet-Biedl Syndrome Patient and Caregiver Perspectives of Hunger and Quality of Life with SetmelanotideGlobeNewsWire • 03/27/23
Rhythm Pharmaceuticals, Inc. (RYTM) Reports Q4 Loss, Tops Revenue EstimatesZacks Investment Research • 03/01/23
Rhythm Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial ResultsGlobeNewsWire • 03/01/23
Rhythm Pharmaceuticals Announces Acquisition of Xinvento B.V. and Portfolio of Investigational TherapeuticsGlobeNewsWire • 02/27/23
Rhythm Pharmaceuticals to Report Fourth Quarter and Full Year 2022 Financial Results on Wednesday, March 1, 2023GlobeNewsWire • 02/21/23
Rhythm Pharmaceuticals Announces Publication of Analysis of Quality of Life Improvements from Phase 3 Clinical Trial in Bardet-Biedl SyndromeGlobeNewsWire • 01/23/23